var data={"title":"Cytarabine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cytarabine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5967?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cytarabine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cytarabine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cytarabine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cytarabine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708668\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Only physicians experienced in cancer chemotherapy should use cytarabine.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Drug toxicities:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">For induction therapy, patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The main toxic effect of cytarabine is bone marrow suppression with leukopenia, thrombocytopenia, and anemia. Less serious toxicity includes nausea, vomiting, diarrhea and abdominal pain, oral ulceration, and hepatic dysfunction.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The physician must judge possible benefit to the patient against known toxic effects of this drug in considering the advisability of therapy with cytarabine. Before making this judgment or beginning treatment, the physician should be familiar with the following text.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155998\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cytarabine Injection;</li>\n      <li>Cytosar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156050\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimetabolite;</li>\n      <li>\n        Antineoplastic Agent, Antimetabolite (Pyrimidine Analog)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156002\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Doses &gt;1000 mg/m<sup>2</sup> are associated with a moderate emetic potential in adults (Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (AML) remission induction:</b> IV: Standard-dose (manufacturer's labeling; in combination with other chemotherapy agents): 100 mg/m<sup>2</sup>/day continuous infusion for 7 days <b>or</b> 200 mg/m<sup>2</sup>/day continuous infusion (as 100 mg/m<sup>2</sup> over 12 hours every 12 hours) for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Indication-specific dosing: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>AML induction:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>7 + 3 regimens (a second induction course may be administered if needed; refer to specific references):</i> 100 mg/m<sup>2</sup>/day continuous infusion for 7 days (in combination with daunorubicin <b>or</b> idarubicin <b>or</b> mitoxantrone) (Arlin, 1990; Dillman, 1991; Fernandez, 2009; Vogler, 1992; Wiernik, 1992) <b>or</b> (Adults &lt;60 years) 200 mg/m<sup>2</sup>/day continuous infusion for 7 days (in combination with daunorubicin) (Dillman, 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Low intensity therapy (off-label dosing):</i> Adults &ge;65 years: SubQ: 20 mg/m<sup>2</sup>/day for 14 days out of every 28-day cycle for at least 4 cycles (Fenaux, 2010) <b>or</b> 10 mg/m<sup>2</sup> every 12 hours for 21 days; if complete response not achieved, may repeat a second course after 15 days (Tilly, 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>AML consolidation (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>5 + 2 regimens:</i> 100 mg/m<sup>2</sup>/day continuous infusion for 5 days (in combination with daunorubicin <b>or</b> idarubicin <b>or</b> mitoxantrone) (Arlin, 1990; Wiernik, 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>5 + 2 + 5 regimen:</i> 100 mg/m<sup>2</sup>/day continuous infusion for 5 days (in combination with daunorubicin <b>and</b> etoposide) (Bishop, 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Single-agent:</i> Adults &le;60 years: 3000 mg/m<sup>2</sup> over 3 hours every 12 hours on days 1, 3, and 5 (total of 6 doses); repeat every 28 to 35 days for 4 courses (Mayer, 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>AML salvage treatment (off-label use): </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CLAG regimen: </i> 2000 mg/m<sup>2</sup>/day over 4 hours for 5 days (in combination with cladribine and G-CSF); may repeat once if needed (Wrzesie&#324;-Ku&#347;, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CLAG-M regimen: </i> 2000 mg/m<sup>2</sup>/day over 4 hours for 5 days (in combination with cladribine, G-CSF, and mitoxantrone); may repeat once if needed (Wierzbowska, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>FLAG regimen: </i> 2000 mg/m<sup>2</sup>/day over 4 hours for 5 days (in combination with fludarabine and G-CSF); may repeat once if needed (Montillo, 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>GCLAC regimen:</i> Adults 18 to 70 years (Becker, 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction</i>: 2,000 mg/m<sup>2</sup> over 2 hours once daily for 5 days (in combination with clofarabine and filgrastim; administer 4 hours after initiation of clofarabine); may repeat induction once if needed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Consolidation:</i> 1,000 mg/m<sup>2</sup> over 2 hours once daily for 5 days (in combination with clofarabine and filgrastim; administer 4 hours after initiation of clofarabine) for 1 or 2 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HiDAC (high-dose cytarabine) &plusmn; an anthracycline: </i> 3000 mg/m<sup>2</sup> over 1 hour every 12 hours for 6 days (total of 12 doses) (Herzig, 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>MEC regimen: </i> 1000 mg/m<sup>2</sup>/day over 6 hours for 6 days (in combination with mitoxantrone and etoposide) (Amadori, 1991) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &lt;60 years: 500 mg/m<sup>2</sup>/day continuous infusion days 1, 2, and 3 and days 8, 9, and 10 (in combination with mitoxantrone and etoposide); may administer a second course if needed (Archimbaud, 1991; Archimbaud, 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute promyelocytic leukemia (APL) induction (off-label dosing):</b> IV: 200 mg/m<sup>2</sup>/day continuous infusion for 7 days beginning on day 3 of treatment (in combination with tretinoin and daunorubicin) (Ades, 2006; Ades, 2008; Powell, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>APL consolidation (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>In combination with idarubicin and tretinoin:</i> High-risk patients (WBC &ge;10,000/mm<sup>3</sup>) (Sanz, 2010): Adults &le;60 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First consolidation course: 1000 mg/m<sup>2</sup>/day for 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third consolidation course: 150 mg/m<sup>2</sup> every 8 hours for 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>In combination with idarubicin, tretinoin, and thioguanine:</i> High-risk patients (WBC &gt;10,000/mm<sup>3</sup>) (Lo Coco, 2010): Adults &le;61 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First consolidation course: 1000 mg/m<sup>2</sup>/day for 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third consolidation course: 150 mg/m<sup>2</sup> every 8 hours for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>In combination with daunorubicin</i> (Ades, 2006; Ades, 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First consolidation course: 200 mg/m<sup>2</sup>/day for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second consolidation course:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Age &le;60 years and low risk (WBC &lt;10,000/mm<sup>3</sup>): 1000 mg/m<sup>2</sup> every 12 hours for 4 days (8 doses)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Age &lt;50 years and high risk (WBC &ge;10,000/mm<sup>3</sup>): 2000 mg/m<sup>2</sup> every 12 hours for 5 days (10 doses)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Age 50 to 60 years and high risk (WBC &ge;10,000/mm<sup>3</sup>): 1500 mg/m<sup>2</sup> every 12 hours for 5 days (10 doses) (Ades, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Age &gt;60 years and high risk (WBC &ge;10,000/mm<sup>3</sup>): 1000 mg/m<sup>2</sup> every 12 hours for 4 days (8 doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphocytic leukemia (ALL; off-label dosing): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction regimen, relapsed or refractory: </i> IV: 3000 mg/m<sup>2</sup> over 3 hours daily for 5 days (in combination with idarubicin [day 3]) (Weiss, 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dose-intensive regimen: </i> IV: 3000 mg/m<sup>2</sup> over 2 hours every 12 hours days 2 and 3 (4 doses/cycle) of even numbered cycles (in combination with methotrexate; alternates with Hyper-CVAD) (Kantarjian, 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CALGB 8811 regimen</i> (Larson, 1995): SubQ</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Early intensification phase: 75 mg/m<sup>2</sup>/dose days 1 to 4 and 8 to 11 (4-week cycle; repeat once)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Late intensification phase: 75 mg/m<sup>2</sup>/dose days 29 to 32 and 36 to 39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Linker protocol:</i> Adults &lt;50 years: IV: 300 mg/m<sup>2</sup>/day days 1, 4, 8, and 11 of even numbered consolidation cycles (in combination with teniposide) (Linker, 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia (CLL; off-label use): </b> <i>OFAR regimen:</i> IV: 1000 mg/m<sup>2</sup>/dose over 2 hours days 2 and 3 every 4 weeks for up to 6 cycles (in combination with oxaliplatin, fludarabine, and rituximab) (Tsimberidou, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary central nervous system (CNS) lymphoma (off-label use): </b> IV: 2000 mg/m<sup>2</sup> over 1 hour every 12 hours days 2 and 3 (total of 4 doses) every 3 weeks (in combination with methotrexate and followed by whole brain irradiation) for a total of 4 courses (Ferreri, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma, relapsed or refractory (off-label use): </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>DHAP regimen:</i> 2000 mg/m<sup>2</sup> over 3 hours every 12 hours day 2 (total of 2 doses/cycle) for 2 cycles (in combination with dexamethasone and cisplatin) (Josting, 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ESHAP regimen:</i> 2000 mg/m<sup>2</sup> day 5 (in combination with etoposide, methylprednisolone, and cisplatin) every 3 to 4 weeks for 3 or 6 cycles (Aparicio, 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mini-BEAM regimen:</i> 100 mg/m<sup>2</sup> every 12 hours days 2 to 5 (total of 8 doses) every 4 to 6 weeks (in combination with carmustine, etoposide, and melphalan) (Colwill, 1995; Martin, 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>BEAM regimen (transplant preparative regimen):</i> 200 mg/m<sup>2</sup> twice daily for 4 days beginning 5 days prior to transplant (in combination with carmustine, etoposide, and melphalan) (Chopra, 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-Hodgkin lymphomas (off-label use): </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CALGB 9251 regimen: </i>Cycles 2, 4, and 6: 150 mg/m<sup>2</sup>/day continuous infusion days 4 and 5 (Lee, 2001; Rizzieri, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CODOX-M/IVAC regimen:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &le;60 years: Cycles 2 and 4 (IVAC): 2000 mg/m<sup>2</sup> every 12 hours days 1 and 2 (total of 4 doses/cycle) (IVAC is combination with ifosfamide, mesna, and etoposide; IVAC alternates with CODOX-M) (Magrath, 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &le;65 years: Cycles 2 and 4 (IVAC): 2000 mg/m<sup>2</sup> over 3 hours every 12 hours days 1 and 2 (total of 4 doses/cycle) (IVAC is combination with ifosfamide, mesna, and etoposide; IVAC alternates with CODOX-M) (Mead, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &gt;65 years: Cycles 2 and 4 (IVAC): 1000 mg/m<sup>2</sup> over 3 hours every 12 hours days 1 and 2 (total of 4 doses/cycle) (IVAC is combination with ifosfamide, mesna, and etoposide; IVAC alternates with CODOX-M) (Mead, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>DHAP regimen:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &le;70 years: 2000 mg/m<sup>2</sup> over 3 hours every 12 hours day 2 (total of 2 doses/cycle) every 3 to 4 weeks for 6 to 10 cycles (in combination with dexamethasone and cisplatin) (Velasquez, 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &gt;70 years: 1000 mg/m<sup>2</sup> over 3 hours every 12 hours day 2 (total of 2 doses/cycle) every 3 to 4 weeks for 6 to 10 cycles (in combination with dexamethasone and cisplatin) (Velasquez, 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ESHAP regimen:</i> 2000 mg/m<sup>2</sup> over 2 hours day 5 every 3 to 4 weeks for 6 to 8 cycles (in combination with etoposide, methylprednisolone, and cisplatin) (Velasquez, 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>BEAM regimen (transplant preparative regimen):</i> 200 mg/m<sup>2</sup> twice daily for 3 days beginning 4 days prior to transplant (in combination with carmustine, etoposide, and melphalan) (Linch, 2010) <b>or</b> 100 mg/m<sup>2</sup> over 1 hour every 12 hours for 4 days beginning 5 days prior to transplant (in combination with carmustine, etoposide, and melphalan) (van Imhoff, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningeal leukemia: </b> Intrathecal: <b>Note:</b> Optimal intrathecal chemotherapy dosing should be based on age rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (Bleyer, 1983; Kerr, 2001). Dosing provided in the manufacturer's labeling is BSA-based (usual dose 30 mg/m<sup>2</sup> every 4 days; range: 5 to 75 mg/m<sup>2</sup> once daily for 4 days or once every 4 days until CNS findings normalize, followed by 1 additional treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Off-label uses or doses for intrathecal therapy: </b> Intrathecal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CNS prophylaxis (ALL):</i> 100 mg weekly for 8 doses, then every 2 weeks for 8 doses, then monthly for 6 doses (high-risk patients) <b>or</b> 100 mg on day 7 or 8 with each chemotherapy cycle for 4 doses (low risk patients) <b>or</b> 16 doses (high-risk patients) (Cortes, 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b> as part of intrathecal triple therapy (TIT): 40 mg days 0 and 14 during induction, days 1, 4, 8, and 11 during CNS therapy phase, every 18 weeks during intensification and maintenance phases (Storring, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CNS prophylaxis (APL, as part of TIT):</i> 50 mg per dose; administer 1 dose prior to consolidation and 2 doses during each of 2 consolidation phases (total of 5 doses) (Ades, 2006; Ades, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CNS leukemia treatment (ALL, as part of TIT):</i> 40 mg twice weekly until CSF cleared (Storring, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CNS lymphoma treatment:</i> 50 mg twice a week for 4 weeks, then weekly for 4-8 weeks, then every other week for 4 weeks, then every 4 weeks for 4 doses (Glantz, 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Leptomeningeal metastases treatment</i>: 25 to 100 mg twice weekly for 4 weeks, then once weekly for 4 weeks, then a maintenance regimen of once a month (Chamberlain, 2010) <b>or</b> 40 to 60 mg per dose (DeAngelis, 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156029\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cytarabine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cytarabine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses &gt;200 mg/m<sup>2</sup> are associated with a moderate emetic potential and 3000 mg/m<sup>2</sup> is associated with a high emetic potential (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (AML) remission induction:</b> IV: Standard-dose (manufacturer's labeling labeling; in combination with other chemotherapy agents): 100 mg/m<sup>2</sup>/day continuous infusion for 7 days <b>or</b> 200 mg/m<sup>2</sup>/day continuous infusion (as 100 mg/m<sup>2</sup> over 12 hours every 12 hours) for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>AML induction: </b>\n      <i>7 + 3 regimen: </i> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;3 years (off-label dosing): 3.3 mg/kg/day continuous infusion for 7 days; minimum of 2 courses (in combination with daunorubicin) (Woods, 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;3 years: 100 mg/m<sup>2</sup>/day continuous infusion for 7 days; minimum of 2 courses (in combination with daunorubicin) (Woods, 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>AML consolidation (off-label use): </b>\n      <i>5 + 2 + 5 regimen: </i> IV: Adolescents &ge;15 years: 100 mg/m<sup>2</sup>/day continuous infusion for 5 days for 2 consolidation courses (in combination with daunorubicin and etoposide) (Bishop, 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>AML salvage treatment (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Clofarabine/Cytarabine regimen: Induction:</i> IV: Children &ge;1 year and Adolescents: 1,000 mg/m<sup>2</sup>/day over 2 hours for 5 days (in combination with clofarabine; cytarabine is administered 4 hours after initiation of clofarabine) for up to 2 induction cycles (Cooper, 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>FLAG regimen: </i> IV: Children &ge;11 years: 2,000 mg/m<sup>2</sup>/day over 4 hours for 5 days (in combination with fludarabine and G-CSF); may repeat once if needed (Montillo, 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>MEC regimen: </i> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years: 1,000 mg/m<sup>2</sup>/day over 6 hours for 6 days (in combination with etoposide and mitoxantrone) (Amadori, 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;15 years: 500 mg/m<sup>2</sup>/day continuous infusion days 1, 2, and 3 and days 8, 9, and 10 (in combination with mitoxantrone and etoposide); may administer a second course if needed (Archimbaud, 1991; Archimbaud, 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphocytic leukemia (ALL; off-label dosing): </b>\n      <i>POG 8602/PVA regimen, intensification phase:</i> IV: Children &ge;1 year: 1,000 mg/m<sup>2</sup> continuous infusion over 24 hours day 1 (beginning 12 hours after start of methotrexate) every 3 weeks or every 12 weeks for 6 cycles (Land, 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-Hodgkin lymphomas (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CODOX-M/IVAC regimen: </i> IV: Children &ge;3 years: Cycles 2 and 4 (IVAC): 2,000 mg/m<sup>2</sup> every 12 hours days 1 and 2 (total of 4 doses/cycle) (IVAC is combination with ifosfamide, mesna and etoposide; IVAC alternates with CODOX-M) (Magrath, 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>High-dose cytarabine: IV:</i> Children &gt;1 year and Adolescents: 3,000 mg/m<sup>2</sup> over 3 hours every 12 hours on days 2 and 3 (secondary phase; total of 4 doses) in combination with methotrexate and intrathecal methotrexate/cytarabine (Bowman, 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningeal leukemia:</b> Intrathecal: <b>Note:</b> Optimal intrathecal chemotherapy dosing should be based on age rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (Bleyer, 1983; Kerr, 2001). Dosing provided in the manufacturer's labeling is BSA-based (usual dose 30 mg/m<sup>2</sup> every 4 days; range: 5 to 75 mg/m<sup>2</sup> once daily for 4 days or once every 4 days until CNS findings normalize, followed by 1 additional treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Age-based intrathecal dosing (off-label; Woods, 1990):</b> Intrathecal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CNS prophylaxis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;1 year: 20 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 1.99 years: 30 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2 to 2.99 years: 50 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;3 years: 70 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ALL CNS prophylaxis, age-specific doses from literature:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Administer on day 0 of induction therapy (Gaynon, 1993):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">1 to &lt;2 years: 30 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">2 to &lt;3 years: 50 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;3 years: 70 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Administer as part of triple intrathecal therapy (TIT) on days 1 and 15 of induction therapy; days 1, 15, 50, and 64 (standard risk patients) or days 1, 15, 29, and 43 (high-risk patients) during consolidation therapy; day 1 of reinduction therapy, and during maintenance therapy (very high-risk patients receive on days 1, 22, 45, and 59 of induction, days 8, 22, 36, and 50 of consolidation therapy, days 8 and 38 of reinduction therapy, and during maintenance) (Lin, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;1 year: 18 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">1 to 2 years: 24 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">2 to 3 years: 30 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;3 years: 36 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Administer on day 0 of induction therapy, then as part of TIT on days 7, 14, and 21 during consolidation therapy; as part of TIT on days 0, 28, and 35 for 2 cycles of delayed intensification therapy, and then maintenance treatment as part of TIT on day 0 every 12 weeks for 38 months (boys) or 26 months (girls) from initial induction treatment (Matloub, 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">1 to &lt;2 years: 16 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">2 to &lt;3 years: 20 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;3 years: 24 to 30 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Administer on day 15 of induction therapy, days 1 and 15 of reinduction phase; and day 1 of cycle 2 of maintenance 1A phase (Pieters, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;1 year: 15 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;1 year: 20 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment, CNS leukemia (ALL): </i>Intrathecal: Administer as part of TIT weekly until CSF remission, then every 4 weeks throughout continuation treatment (Lin, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;1 year: 18 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 2 years: 24 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2 to 3 years: 30 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;3 years: 36 mg per dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156003\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156004\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aronoff, 2007 (cytarabine 100 to 200 mg/m<sup>2</sup>): Children and Adults: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kintzel, 1995 (high-dose cytarabine 1 to 3 g/m<sup>2</sup>):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 46 to 60 mL/minute: Administer 60% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 31 to 45 mL/minute: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;30 mL/minute: Consider use of alternative drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Smith, 1997 (high-dose cytarabine; &ge;2 g/m<sup>2</sup>/dose): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Serum creatinine 1.5 to 1.9 mg/dL or increase (from baseline) of 0.5 to 1.2 mg/dL: Reduce dose to 1 g/m<sup>2</sup>/dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Serum creatinine &ge;2 mg/dL or increase (from baseline) of &gt;1.2 mg/dL: Reduce dose to 0.1 g/m<sup>2</sup>/day as a continuous infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemodialysis: In 4 hour dialysis sessions (with high flow polysulfone membrane) 6 hours after cytarabine 1 g/m<sup>2</sup> over 2 hours, 63% of the metabolite ARA-U was extracted from plasma (based on a single adult case report) (Radeski, 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156005\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Dose may need to be adjusted in patients with liver failure since cytarabine is partially detoxified in the liver. There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Floyd, 2006: Transaminases (any elevation): Administer 50% of dose; may increase subsequent doses in the absence of toxicities</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Koren, 1992 (dose level not specified):  Bilirubin &gt;2 mg/dL: Administer 50% of dose; may increase subsequent doses in the absence of toxicities</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20340178\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;\">\n      <i>American Society of Clinical Oncology (ASCO) Guidelines for appropriate chemotherapy dosing in obese adults with cancer (excludes leukemias):</i>Utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize actual body weight (full weight) for calculation of body surface area in cytarabine dosing for hematopoietic stem cell transplant conditioning regimens in pediatrics and adults (Bubalo 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155976\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/mL (25 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/mL (5 mL, 50 mL); 100 mg/mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (1 ea); 500 mg (1 ea); 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155961\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155979\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse standard dose therapy for AML (100 to 200 mg/m<sup>2</sup>/day) as a continuous infusion. Infuse high-dose therapy (off-label) over 1 to 3 hours (usually). Other rates have been used, refer to specific reference.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">In adults, doses &gt;1,000 mg/m<sup>2</sup> are associated with a moderate emetic potential (Hesketh 2017; Roila 2016). In pediatrics, doses &gt;200 mg/m<sup>2</sup> are associated with a moderate emetic potential and 3,000 mg/m<sup>2</sup> is associated with a high emetic potential (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal: Intrathecal doses should be administered as soon as possible after preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">May also be administered SubQ.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130965\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155977\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia:</b> Remission induction (in combination with other chemotherapy medications) in acute myeloid leukemia (AML)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphocytic leukemia:</b> Treatment of acute lymphocytic leukemia (ALL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic myeloid leukemia:</b> Treatment of chronic myeloid leukemia (CML; blast phase)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningeal leukemia:</b> Prophylaxis and treatment of meningeal leukemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722038\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute promyelocytic leukemia (induction); Acute promyelocytic leukemia (consolidation); Acute myeloid leukemia (consolidation); Acute myeloid leukemia (salvage); Chronic lymphocytic leukemia (refractory); Primary central nervous system lymphoma; Hodgkin lymphoma (relapsed or refractory); Non-Hodgkin lymphoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156059\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytarabine may be confused with clofarabine, Cytosar, Cytoxan, vidarabine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytarabine (conventional) may be confused with cytarabine liposomal</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytarabine (conventional) (100 mg/5 mL; Hospira manufacturer) may be confused with vinorelbine (50 mg/5 mL; Hospira manufacturer) due to similar packaging; potential for inadvertent intrathecal administration of vinorelbine may occur (ISMP, [Smetzer 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytosar-U may be confused with cytarabine, Cytovene, Cytoxan, Neosar</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n          <i>Intrathecal medication safety:</i> The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson, 2009) encourage the following safety measures for intrathecal chemotherapy:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">&bull; Intrathecal medication should not be prepared during the preparation of any other agents</p>\n        <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">&bull; After preparation, store in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only</p>\n        <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">&bull; Delivery to the patient should only be with other medications also intended for administration into the central nervous system</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155968\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined. CNS, gastrointestinal, ophthalmic, and pulmonary toxicities are more common with high-dose regimens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, chest pain, local thrombophlebitis, pericarditis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Aseptic meningitis, cerebral dysfunction, dizziness, headache, neuritis, neurotoxicity, paralysis (intrathecal and IV combination therapy), reversible posterior leukoencephalopathy syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acute generalized exanthematous pustulosis, alopecia, dermal ulcer, ephelis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperuricemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anal fissure, anorexia, diarrhea, esophageal ulcer, esophagitis, increased serum amylase, increased serum lipase, intestinal necrosis, mucositis, nausea, pancreatitis, sore throat, toxic megacolon, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bone marrow depression, hemorrhage, leukopenia, megaloblastic anemia, neutropenia (onset: 1 to 7 days; nadir [biphasic]: 7 to 9 days and at 15 to 24 days; recovery [biphasic]: 9 to 12 days and at 24 to 34 days), reticulocytopenia, thrombocytopenia (onset: 5 days; nadir: 12 to 15 days; recovery 15 to 25 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic insufficiency, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), increased serum transaminases (acute), jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Allergic edema, anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Cellulitis at injection site, inflammation at injection site (SC injection), local inflammation (anus), pain at injection site (SC injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Rhabdomyolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Acute respiratory distress, dyspnea, interstitial pneumonitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Drug toxicity (cytarabine syndrome; chest pain, conjunctivitis, fever, maculopapular rash, malaise, myalgia, ostealgia), fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adverse events associated with high-dose cytarabine</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiomegaly, cardiomyopathy (in combination with cyclophosphamide)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Neurotoxicity (patients with renal impairment: &le;55%), coma, drowsiness, neurocerebellar toxicity, peripheral neuropathy (motor and sensory), personality changes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (complete), desquamation, skin rash (severe)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal ulcer, necrotizing enterocolitis, pancreatitis, peritonitis, pneumatosis cystoides intestinalis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic abscess, hepatic injury, hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Corneal toxicity, hemorrhagic conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Acute respiratory distress, pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adverse events associated with intrathecal cytarabine administration</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Aphonia, leukoencephalopathy (necrotizing; with concurrent cranial irradiation, intrathecal methotrexate, and intrathecal hydrocortisone), nerve palsy (accessory nerve), neurotoxicity, paraplegia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysphagia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blindness (with concurrent systemic chemotherapy and cranial irradiation), diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, hoarseness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155982\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cytarabine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155965\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Myelosuppression (leukopenia, thrombocytopenia and anemia) is the major toxicity of cytarabine.</b> Use with caution in patients with prior drug-induced bone marrow suppression. Monitor blood counts frequently; once blasts are no longer apparent in the peripheral blood, bone marrow should be monitored frequently. Monitor for signs of infection or neutropenic fever due to neutropenia or bleeding due to thrombocytopenia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytarabine syndrome: Cytarabine (ARA-C) syndrome is characterized by fever, myalgia, bone pain, chest pain (occasionally), maculopapular rash, conjunctivitis, and malaise; generally occurs 6 to 12 hours following administration. May be managed with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicities:<b> [US Boxed Warning]: Toxicities (less serious) include nausea, vomiting, diarrhea, abdominal pain, oral ulcerations and hepatic dysfunction.</b> In adults, doses &gt;1000 mg/m<sup>2</sup> are associated with a moderate emetic potential (Hesketh 2017; Roila 2016). In pediatrics, doses &gt;200 mg/m<sup>2</sup> are associated with a moderate emetic potential and 3000 mg/m<sup>2</sup> is associated with a high emetic potential (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylaxis resulting in acute cardiopulmonary arrest has been reported (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: There have been reports of acute pancreatitis in patients receiving continuous infusion cytarabine and in patients receiving cytarabine who were previously treated with L-asparaginase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sudden respiratory distress syndrome: Sudden respiratory distress, rapidly progressing to pulmonary edema and cardiomegaly, has been reported with high-dose cytarabine. May present as severe dyspnea with a rapid onset and refractory hypoxia with diffuse pulmonary infiltrates, leading to respiratory failure; may be fatal (Morgan 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome and subsequent hyperuricemia may occur; consider antihyperuricemic therapy and hydrate accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may be at higher risk for CNS toxicities and dosage adjustments may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with impaired renal function (high dose cytarabine); may be at higher risk for CNS toxicities and dosage adjustments may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. There have been case reports of fatal cardiomyopathy when high-dose cytarabine was used in combination with cyclophosphamide as a preparation regimen for transplantation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Delayed progressive ascending paralysis has been reported in two children who received combination chemotherapy with IV and intrathecal cytarabine at conventional doses for the treatment of acute myeloid leukemia (was fatal in one patient).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol: Some products may contain benzyl alcohol; do not use products containing benzyl alcohol or products reconstituted with bacteriostatic diluent intrathecally or for high-dose cytarabine regimens. Benzyl alcohol is associated with gasping syndrome in premature infants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician. Due to the potential toxicities, induction treatment with cytarabine should be in a facility with sufficient laboratory and supportive resources. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; High-dose treatment: High-dose regimens have been associated with GI, CNS, pulmonary, ocular (reversible corneal toxicity and hemorrhagic conjunctivitis; prophylaxis with ophthalmic corticosteroids is recommended) toxicities, and cardiomyopathy. Neurotoxicity associated with high-dose treatment may present as acute cerebellar toxicity (with or without cerebral impairment), personality changes, or may be severe with seizure and/or coma; may be delayed, occurring up to 3 to 8 days after treatment has begun; possibly irreversible. Risk factors for neurotoxicity include cumulative cytarabine dose, prior CNS disease and renal impairment (incidence may be up to 55% in patients with renal impairment); high-dose therapy (&gt;18 g/m<sup>2</sup> per cycle) and age &gt;50 years also increase the risk for cerebellar toxicity (Herzig 1987).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intrathecal safety: When used for intrathecal administration, should not be prepared during the preparation of any other agents. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only. Delivery of intrathecal medications to the patient should only be with other medications also intended for administration into the central nervous system (Jacobson 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299114\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155970\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9314&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucytosine: Cytarabine (Conventional) may diminish the therapeutic effect of Flucytosine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155972\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155985\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were demonstrated in animal reproduction studies. Limb and ear defects have been noted in case reports of cytarabine exposure during the first trimester of pregnancy. The following have also been noted in the neonate: Pancytopenia, WBC depression, electrolyte abnormalities, prematurity, low birth weight, decreased hematocrit or platelets. Risk to the fetus is decreased if treatment can be avoided during the first trimester; however, women of childbearing potential should be advised of the potential risks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5375699\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if cytarabine is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the decision to discontinue cytarabine or to discontinue breastfeeding should take into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155974\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests, CBC with differential and platelet count, serum creatinine, BUN, serum uric acid</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155964\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits DNA synthesis. Cytarabine gains entry into cells by a carrier process, and then must be converted to its active compound, aracytidine triphosphate. Cytarabine is a pyrimidine analog and is incorporated into DNA; however, the primary action is inhibition of DNA polymerase resulting in decreased DNA synthesis and repair. The degree of cytotoxicity correlates linearly with incorporation into DNA; therefore, incorporation into the DNA is responsible for drug activity and toxicity. Cytarabine is specific for the S phase of the cell cycle (blocks progression from the G<sub>1</sub> to the S phase). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155981\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Not effective when administered orally; less than 20% absorbed orally </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 3 &plusmn; 11.9 L/kg; total body water; widely and rapidly since it enters the cells readily; crosses blood-brain barrier with CSF levels of 40% to 50% of plasma level </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 13%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily hepatic; metabolized by deoxycytidine kinase and other nucleotide kinases to aracytidine triphosphate (active); about 86% to 96% of dose is metabolized to inactive uracil arabinoside (ARA-U); intrathecal administration results in little conversion to ARA-U due to the low levels of deaminase in the cerebral spinal fluid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: Initial: 7 to 20 minutes; Terminal: 1 to 3 hours; Intrathecal: 2 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: SubQ: 20 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~80%; 90% as metabolite ARA-U) within 24 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323088\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cytarabine (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (5 mL): $7.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (20 mL): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cytarabine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (25 mL): $18.41</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155986\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aleksan (UA);</li>\n      <li>Alexan (AE, AT, BG, CH, CL, CZ, DK, EC, GB, HK, HN, HR, HU, ID, IE, IT, JO, LB, MT, PL, PT, QA, RO, RU, SA, SE, SI, SK, TH, TR, VN, ZA);</li>\n      <li>Ara-C (AR);</li>\n      <li>Arabine (DK, FI, FR);</li>\n      <li>Arabitin (JP);</li>\n      <li>Aracytin (CO, GR, IT, UY);</li>\n      <li>Aracytine (FR);</li>\n      <li>Cancyt (PH);</li>\n      <li>Citafam (AR);</li>\n      <li>Citarabina (ES);</li>\n      <li>Cyclocide (TW);</li>\n      <li>Cylocide (JP);</li>\n      <li>Cytabin (BD);</li>\n      <li>Cytarabin (DE, NO);</li>\n      <li>Cytarabine (AU);</li>\n      <li>Cytarabine Injection (AU, GB, NZ);</li>\n      <li>Cytarabinum-Delta West (LU);</li>\n      <li>Cytarine (IN, SG, TH, VN, ZW);</li>\n      <li>Cytonal (RU, TR);</li>\n      <li>Cytosa U (KR);</li>\n      <li>Cytosar (AE, AT, BE, BG, BH, CH, CN, CY, CZ, EE, EG, FI, GB, GH, HK, HN, HR, HU, IL, IQ, IR, JO, KE, KW, LB, LU, LV, LY, NL, OM, PE, PK, PT, QA, RO, SA, SY, TH, TZ, UG, VN, YE, ZM);</li>\n      <li>Cytosar-U (ID, KR, MY, VE);</li>\n      <li>Cytox (PH);</li>\n      <li>Cytrostar (LK);</li>\n      <li>Darbin (BR, PY);</li>\n      <li>Laracit (CO, CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Medsara (MX);</li>\n      <li>Mokcell (PE);</li>\n      <li>Moxell (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Oncotar (LK);</li>\n      <li>Saidewei (CN);</li>\n      <li>Starasid (JP);</li>\n      <li>Tabine (PH);</li>\n      <li>Tarabin (BD);</li>\n      <li>Tsytozar (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17116939\"></a>Ad&egrave;s L, Chevret S, Raffous, et al, &ldquo;Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group,&rdquo; <i>J Clin Oncol</i>, 2006, 24(36):5703-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/17116939/pubmed\" target=\"_blank\" id=\"17116939\">17116939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17975017\"></a>Ad&egrave;s L, Sanz MA, Chevret S, et al, &ldquo;Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison of French-Belgian-Swiss and PETHEMA Results,&rdquo; <i>Blood</i>, 2008, 111(3):1078-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/17975017/pubmed\" target=\"_blank\" id=\"17975017\">17975017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2045861\"></a>Amadori S, Arcese W, Isacchi G, et al, &ldquo;Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine: An Effective and Tolerable Regimen for the Treatment of Refractory Acute Myeloid Leukemia,&rdquo; <i>J Clin Oncol</i>, 1991, 9(7):1210-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/2045861/pubmed\" target=\"_blank\" id=\"2045861\">2045861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10416011\"></a>Aparicio J, Segura A, Garcer&aacute; S, et al, &ldquo;ESHAP is an Active Regimen for Relapsing Hodgkin's Disease,&rdquo; <i>Ann Oncol</i>, 1999, 10(5):593-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/10416011/pubmed\" target=\"_blank\" id=\"10416011\">10416011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2018832\"></a>Archimbaud E, Leblond V, Michallet M, et al. &ldquo;Intensive Sequential Chemotherapy With Mitoxantrone and Continuous Infusion Etoposide and Cytarabine for Previously Treated Acute Myelogenous Leukemia,&rdquo; <i>Blood</i>, 1991, 77(9):1894-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/2018832/pubmed\" target=\"_blank\" id=\"2018832\">2018832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7799010\"></a>Archimbaud E, Thomas X, Leblond V, et al, &quot;Timed Sequential Chemotherapy for Previously Treated Patients With Acute Myeloid Leukemia: Long-Term Follow-Up of the Etoposide, Mitoxantrone, and Cytarabine-86 Trial,&quot; <i>J Clin Oncol</i>, 1995, 13(1):11-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/7799010/pubmed\" target=\"_blank\" id=\"7799010\">7799010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2179638\"></a>Arlin Z, Case DC Jr, Moore J, et al, &ldquo;Randomized Multicenter Trial of Cytosine Arabinoside With Mitoxantrone or Daunorubicin in Previously Untreated Adult Patients With Acute Nonlymphocytic Leukemia (ANLL). Lederle Cooperative Group,&rdquo; <i>Leukemia</i>, 1990, 4(3):177-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/2179638/pubmed\" target=\"_blank\" id=\"2179638\">2179638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 98, 170.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21848522\"></a>Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. <i>Br J Haematol</i>. 2011;155(2):182-189. doi:10.1111/j.1365-2141.2011.08831.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/21848522/pubmed\" target=\"_blank\" id=\"21848522\">21848522</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8634416\"></a>Bishop JF, Matthews JP, Young GA, et al, &quot;A Randomized Study of High-Dose Cytarabine in Induction in Acute Myeloid Leukemia,&quot; <i>Blood</i>, 1996, 87(5):1710-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/8634416/pubmed\" target=\"_blank\" id=\"8634416\">8634416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleyer WA, Coccia PF, Sather HN, et al, &ldquo;Reduction in Central Nervous System Leukemia With a Pharmacokinetically Derived Intrathecal Methotrexate Dosage Regimen,&rdquo; <i>J Clin Oncol</i>, 1983, 1(5):317-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/6366138/pubmed\" target=\"_blank\" id=\"6366138\">6366138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. <i>J Clin Oncol</i>. 1996; 14(4):1252-1261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/8648381/pubmed\" target=\"_blank\" id=\"8648381\">8648381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.<i> Biol Blood Marrow Transplant</i>. 2014;20(5):600-616. doi: 10.1016/j.bbmt.2014.01.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/24462742/pubmed\" target=\"_blank\" id=\"24462742\">24462742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. <i>J Clin Oncol</i>. 2013;31(27):3360-3368. doi: 10.1200/JCO.2012.47.4874.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/23940227/pubmed\" target=\"_blank\" id=\"23940227\">23940227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cassileth PA, Harrington DP, Appelbaum FR, et al, &ldquo;Chemotherapy Compared With Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission,&rdquo; <i>N Engl J Med</i>, 1998, 339(23):1649-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/9834301/pubmed\" target=\"_blank\" id=\"9834301\">9834301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chamberlain MC. Leptomeningeal metastasis. <i>Curr Opin Oncol</i>. 2010;22(6):627-635.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/20689429/pubmed\" target=\"_blank\" id=\"20689429\">20689429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheung YW, Vishnuvajjala BR, Flora KP. Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. <i>Am J Hosp Pharm</i>. 1984;41(9):1802-1806.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/6496516/pubmed\" target=\"_blank\" id=\"6496516\">6496516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chiu A, Kohler S, McGuire J, et al, &ldquo;Cytarabine-Induced Acute Generalized Exanthematous Pustulosis,&rdquo; <i>J Am Acad Dermatol</i>, 2002, 47(4):633-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8443375\"></a>Chopra R, McMillan AK, Linch DC, et al, &ldquo;The Place of High-Dose BEAM Therapy and Autologous Bone Marrow Transplantation in Poor-Risk Hodgkin's Disease. A Single-Center Eight-Year Study of 155 Patients,&rdquo; <i>Blood</i>, 1993, 81(5):1137-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/8443375/pubmed\" target=\"_blank\" id=\"8443375\">8443375</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7844600\"></a>Colwill R, Crump M, Couture F, et al,, &ldquo;Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin's Disease Before Intensive Therapy and Autologous Bone Marrow Transplantation,&rdquo; <i>J Clin Oncol</i>, 1995, 13(2):396-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/7844600/pubmed\" target=\"_blank\" id=\"7844600\">7844600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper TM, Alonzo TA, Gerbing RB, et al. AAML0523: A report from the Children&rsquo;s Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. <i>Cancer</i>. 2014 [Epub ahead of print]. doi: 10.1002/cncr.28674.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/24771494/pubmed\" target=\"_blank\" id=\"24771494\">24771494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes J, O&rsquo;Brien SM, Pierce S, et al, &ldquo;The Value of High-Dose Systemic Chemotherapy and Intrathecal Therapy for Central Nervous System Prophylaxis in Different Risk Groups of Adult Acute Lymphoblastic Leukemia,&rdquo; <i>Blood</i>, 1995, 86(6):2091-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/7662956/pubmed\" target=\"_blank\" id=\"7662956\">7662956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cytarabine (prescribing information). Rockford, Il: Mylan Institutional; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeAngelis LM and Boutros D, &ldquo;Leptomeningeal Metastasis,&rdquo; <i>Cancer Invest</i>, 2005, 23(2):145-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/15813508/pubmed\" target=\"_blank\" id=\"15813508\">15813508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Lemos ML, Monfared S, Denyssevych T, et al, &ldquo;Evaluation of Osmolality and pH of Various Concentrations of Methotrexate, Cytarabine, and Thiotepa Prepared in Normal Saline, Sterile Water for Injection, and Lactated Ringers&rsquo;s Solution for Intrathecal Administration,&rdquo; <i>J Oncol Pharm Pract</i>, 2009, 15(1):45-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/18772215/pubmed\" target=\"_blank\" id=\"18772215\">18772215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dillman RO, Davis RB, Green MR, et al, &ldquo;A Comparative Study of Two Different Doses of Cytarabine for Acute Myeloid Leukemia: A Phase III Trial of Cancer and Leukemia Group B,&rdquo; <i>Blood</i>, 1991, 78(10):2520-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/1824249 /pubmed\" target=\"_blank\" id=\"1824249 \">1824249 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D&ouml;hner H, Estey EH, Amadori S, et al, &ldquo;Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations From an International Expert Panel, on Behalf of the European LeukemiaNet,&rdquo; <i>Blood</i>, 2010, 115(3):453-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/19880497/pubmed\" target=\"_blank\" id=\"19880497\">19880497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al, &ldquo;Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia, <i>J Clin Oncol</i>, 2010, 28(4):562-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/20026804/pubmed\" target=\"_blank\" id=\"20026804\">20026804</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fernandez HF, Sun Z, Yao X, et al, &ldquo;Anthracycline Dose Intensification in Acute Myeloid Leukemia,&rdquo; <i>N Engl J Med</i>, 2009, 361(13):1249-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/19776406/pubmed\" target=\"_blank\" id=\"19776406\">19776406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19767089\"></a>Ferreri AJ, Reni M, Foppoli M, et al, &ldquo;High-Dose Cytarabine Plus High-Dose Methotrexate Versus High-Dose Methotrexate Alone in Patients With Primary CNS Lymphoma: a Randomised Phase 2 Trial,&rdquo; <i>Lancet</i>, 2009, 374(9700):1512-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/19767089/pubmed\" target=\"_blank\" id=\"19767089\">19767089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &quot;Hepatotoxicity of Chemotherapy,&quot; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo; <i>J Clin Oncol</i>, 2005, 23(30):7685-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/16234530/pubmed\" target=\"_blank\" id=\"16234530\">16234530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardin C, Turlure P, Fagot T, et al, &ldquo;Postremission Treatment of Elderly Patients With Acute Myeloid Leukemia in First Complete Remission After Intensive Induction Chemotherapy: Results of the Multicenter Randomized Acute Leukemia French Association (ALFA) 9803 Trial,&rdquo; <i>Blood</i>, 2007, 109(12):5129-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/17341661/pubmed\" target=\"_blank\" id=\"17341661\">17341661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaynon PS, Steinherz PG, Bleyer WA, et al, &ldquo;Improved Therapy for Children With Acute Lymphoblastic Leukemia and Unfavorable Presenting Features: A Follow-Up Report of the Childrens Cancer Group Study CCG-106,&rdquo; <i>J Clin Oncol</i>, 1993, 11(11):2234-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/8229139/pubmed\" target=\"_blank\" id=\"8229139\">8229139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glantz MJ, LaFollette S, Jaeckle KA, et al, &ldquo;Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis,&rdquo; <i>J Clin Oncol</i>, 1999, 17(10):3110-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/10506606/pubmed\" target=\"_blank\" id=\"10506606\">10506606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guilhot F, Chastang C, Michallet M, et al, &quot;Interferon Alfa-2b Combined With Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia. French Chronic Myeloid Leukemia Study Group,&quot; <i>N Engl J Med</i>, 1997, 337(4):223-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/ 9227927/pubmed\" target=\"_blank\" id=\" 9227927\"> 9227927</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herzig RH, Hines JD, Herzig GP, et al, &ldquo;Cerebellar Toxicity With High-Dose Cytosine Arabinoside,&rdquo; <i>J Clin Oncol</i>, 1987, 5(6):927-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/3585447/pubmed\" target=\"_blank\" id=\"3585447\">3585447</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3894588\"></a>Herzig RH, Lazarus HM, Wolff SN, et al, &ldquo;High-Dose Cytosine Arabinoside Therapy With and Without Anthracycline Antibiotics for Remission Reinduction of Acute Nonlymphoblastic Leukemia,&rdquo; <i>J Clin Oncol</i>, 1985, 3(7):992-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/3894588/pubmed\" target=\"_blank\" id=\"3894588\">3894588</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hiddemann W, &ldquo;Cytosine Arabinoside in the Treatment of Acute Myeloid Leukemia: The Role and Place of High-Dose Regimens,&rdquo; <i>Ann Hematol</i>, 1991, 62(4):119-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/2031974/pubmed\" target=\"_blank\" id=\"2031974\">2031974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson JO, Polovich M, McNiff KK, et al, &quot;American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,&quot; <i>J Clin Oncol</i>, 2009, 27(32):5469-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/19786650/pubmed\" target=\"_blank\" id=\"19786650\">19786650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12377653\"></a>Josting A, Rudolph C, Reiser M, et al, &ldquo;Time-Intensified Dexamethasone/Cisplatin/Cytarabine: An Effective Salvage Therapy With Low Toxicity in Patients With Relapsed and Refractory Hodgkin's Disease,&rdquo; <i>Ann Oncol</i>, 2002, 13(10):1628-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/12377653/pubmed\" target=\"_blank\" id=\"12377653\">12377653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian HM, O'Brien S, Smith TL, et al, &ldquo;Results of Treatment With Hyper-CVAD, A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia,&rdquo; <i>J Clin Oncol</i>, 2000, 18(3): 547-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/10653870 /pubmed\" target=\"_blank\" id=\"10653870 \">10653870 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kerr JZ, Berg S, and Blaney SM, &ldquo;Intrathecal Chemotherapy,&rdquo; <i>Crit Rev Oncol Hematol</i>, 2001, 37(3):227-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/11248578/pubmed\" target=\"_blank\" id=\"11248578\">11248578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren G, Beatty K, Seto A, et al, &ldquo;The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents,&rdquo; <i>Ann Pharmacother</i>, 1992, 26(3):363-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/1554959/pubmed\" target=\"_blank\" id=\"1554959\">1554959</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Land VJ, Shuster JJ, Crist WM, et al, &ldquo;Comparison of Two Schedules of Intermediate-Dose Methotrexate and Cytarabine Consolidation Therapy for Childhood B-Precursor Cell Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study,&rdquo; <i>J Clin Oncol</i>, 1994, 12(9):1939-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/8083715 /pubmed\" target=\"_blank\" id=\"8083715 \">8083715 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larson RA, Dodge RK, Burns CP, et al, &ldquo;A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,&rdquo; <i>Blood</i>, 1995, 85(8):2025-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/7718875 /pubmed\" target=\"_blank\" id=\"7718875 \">7718875 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11600602\"></a>Lee EJ, Petroni GR, Schiffer CA, et al, &ldquo;Brief-Duration High-Intensity Chemotherapy for Patients With Small Noncleaved-Cell Lymphoma or FAB L3 Acute Lymphocytic Leukemia: Results of Cancer and Leukemia Group B Study 9251,&rdquo; <i>J Clin Oncol</i>, 2001, 19(20):4014-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/11600602/pubmed\" target=\"_blank\" id=\"11600602\">11600602</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin WY, Liu HC, Yeh TC, et al, &ldquo;Triple Intrathecal Therapy Without Cranial Irradiation for Central Nervous System Preventive Therapy in Childhood Acute Lymphoblastic Leukemia,&rdquo; <i>Pediatr Blood Cancer</i>, 2008, 50(3):523-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/17455314/pubmed\" target=\"_blank\" id=\"17455314\">17455314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20201949\"></a>Linch DC, Yung L, Smith P, et al, &ldquo;Final Analysis of the UKLG LY02 Trial Comparing 6-8 Cycles of CHOP With 3 Cycles of CHOP Followed by a BEAM Autograft in Patients &lt;65 Years With Poor Prognosis Histologically Aggressive NHL,&rdquo; <i>Br J Haematol</i>, 2010, 149(2):237-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/20201949/pubmed\" target=\"_blank\" id=\"20201949\">20201949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linker CA, Levitt LJ, O'Donnell M, et al, &ldquo;Treatment of Adult Acute Lymphoblastic Leukemia With Intensive Cyclical Chemotherapy: A Follow-up Report,&rdquo; <i>Blood</i>, 1991, 78(11):2814-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/1835410 /pubmed\" target=\"_blank\" id=\"1835410 \">1835410 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20644121\"></a>Lo Coco F, Avvisati G, Vignetti M, et al, &ldquo;Front-Line Treatment of Acute Promyelocytic Leukemia With AIDA Induction Followed by Risk-Adapted Consolidation for Adults Younger Than 61 Years: Results of the AIDA-2000 Trial of the GIMEMA Group,&rdquo; <i>Blood</i>, 2010, 116(17):3171-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/20644121/pubmed\" target=\"_blank\" id=\"20644121\">20644121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    L&ouml;wenberg B, Pabst T, Vellenga E, et al, &ldquo;Cytarabine Dose for Acute Myeloid Leukemia,&rdquo; <i>N Engl J Med</i>, 2011, 364(11):1027-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/21410371/pubmed\" target=\"_blank\" id=\"21410371\">21410371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8622041\"></a>Magrath I, Adde M, Shad A, et al, &quot;Adults and Children With Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated With the Same Chemotherapy Regimen,&quot; <i>J Clin Oncol</i>, 1996, 14(3):925-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/8622041/pubmed\" target=\"_blank\" id=\"8622041\">8622041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11328296\"></a>Mart&iacute;n A, Fern&aacute;ndez-Jim&eacute;nez MC, Caballero MD, et al. &ldquo;Long-Term Follow-Up in Patients Treated With Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin's Disease,&rdquo; <i>Br J Haematol</i>, 2001, 113(1):161-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/11328296/pubmed\" target=\"_blank\" id=\"11328296\">11328296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matloub Y, Lindemulder S, Gaynon PS, et al, &ldquo;Intrathecal Triple Therapy Decreases Central Nervous System Relapse but Fails to Improve Event-Free Survival When Compared With Intrathecal Methotrexate: Results of the Children's Cancer Group (CCG) 1952 Study for Standard-Risk Acute Lymphoblastic Leukemia, Reported by the Children's Oncology Group,&rdquo; <i>Blood</i>, 2006, 108(4):1165-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/16609069/pubmed\" target=\"_blank\" id=\"16609069\">16609069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8078551\"></a>Mayer RJ, Davis RB, Schiffer CA, et al, &quot;Intensive Postremission Chemotherapy in Adults With Acute Myeloid Leukemia, Cancer and Leukemia Group B,&quot; <i>N Engl J Med</i>, 1994, 331(14):896-903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/8078551/pubmed\" target=\"_blank\" id=\"8078551\">8078551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18612102\"></a>Mead GM, Barrans SL, Qian W, et al, &quot;A Prospective Clinicopathologic Study of Dose-Modified CODOX-M/IVAC in Patients With Sporadic Burkitt Lymphoma Defined Using Cytogenetic and Immunophenotypic Criteria (MRC/NCRI LY10 Trial),&quot; <i>Blood</i>, 2008, 112(6):2248-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/18612102/pubmed\" target=\"_blank\" id=\"18612102\">18612102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milligan DW, Wheatley K, Littlewood T, et al, &ldquo;Fludarabine and Cytosine are Less Effective than Standard ADE Chemotherapy in High-Risk Acute Myeloid Leukemia, and Addition of G-CSF and ATRA are not Beneficial: Results of the MRC AML-HR Randomized Trial,&rdquo; <i>Blood</i>, 2006, 107(12):4614-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/16484584/pubmed\" target=\"_blank\" id=\"16484584\">16484584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9625576\"></a>Montillo M, Mirto S, Petti MC, et al, &quot;Fludarabine, Cytarabine, and G-CSF (FLAG) for the Treatment of Poor Risk Acute Myeloid Leukemia,&quot; <i>Am J Hematol</i>, 1998, 58(2):105-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/9625576/pubmed\" target=\"_blank\" id=\"9625576\">9625576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo; <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/21276754/pubmed\" target=\"_blank\" id=\"21276754\">21276754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pease CL, Horton TM, McClain KL, et al, &ldquo;Aseptic Meningitis in a Child After Systemic Treatment With High Dose Cytarabine,&rdquo; <i>Pediatr Infect Dis J</i>, 2001, 20(1):87-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/11176579/pubmed\" target=\"_blank\" id=\"11176579\">11176579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pegram AA and Kennedy LD, &ldquo;Prevention and Treatment of Veno-Occlusive Disease,&rdquo; <i>Ann Pharmacother</i>, 2001, 35(7-8):935-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/11485147/pubmed\" target=\"_blank\" id=\"11485147\">11485147</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pieters R, Schrappe M, De Lorenzo P, et al, &ldquo;A Treatment Protocol for Infants Younger Than 1 Year With Acute Lymphoblastic Leukaemia (Interfant-99): An Observational Study and a Multicentre Randomised Trial,&rdquo; <i>Lancet</i>, 2007, 370(9583):240-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/17658395/pubmed\" target=\"_blank\" id=\"17658395\">17658395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20705755\"></a>Powell BL, Moser B, Stock W, et al, &ldquo;Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,&rdquo; <i>Blood</i>, 2010, 116(19):3751-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/20705755/pubmed\" target=\"_blank\" id=\"20705755\">20705755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Radeski D, Cull GM, Cain M, et al, &ldquo;Effective Clearance of Ara-U the Major Metabolite of Cytosine Arabinoside (Ara-C) by Hemodialysis in a Patient With Lymphoma and End-Stage Renal Failure,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2011, 67(4):765-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/20532508/pubmed\" target=\"_blank\" id=\"20532508\">20532508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15042678\"></a>Rizzieri DA, Johnson JL, Niedzwiecki D, et al, &ldquo;Intensive Chemotherapy With and Without Cranial Radiation for Burkitt Leukemia and Lymphoma: Final Results of Cancer and Leukemia Group B Study 9251,&rdquo; <i>Cancer</i>, 2004, 100(7):1438-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/15042678/pubmed\" target=\"_blank\" id=\"15042678\">15042678</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanz MA, Grimwade D, Tallman MS, et al, &ldquo;Management of Acute Promyelocytic Leukemia: Recommendations From an Expert Panel on Behalf of the European LeukemiaNet,&rdquo; <i>Blood</i>, 2009, 113(9):1875-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/18812465/pubmed\" target=\"_blank\" id=\"18812465\">18812465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20393132\"></a>Sanz MA, Montesinos P, Ray&oacute;n C, et al, &ldquo;Risk-Adapted Treatment of Acute Promyelocytic Leukemia Based on all-trans Retinoic Acid and Anthracycline With Addition of Cytarabine in Consolidation Therapy for High-Risk Patients: Further Improvements in Treatment Outcome,&rdquo; <i>Blood</i>, 2010, 115(25):5137-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/20393132/pubmed\" target=\"_blank\" id=\"20393132\">20393132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith G, Damon LE, Rugo HS, et al. &ldquo;High-Dose Cytarabine Dose Modification Reduces the Incidence of Neurotoxicity in Patients With Renal Insufficiency,&rdquo; <i>J Clin Oncol</i>, 1997, 15(2): 833-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/9053511/pubmed\" target=\"_blank\" id=\"9053511\">9053511</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stasi R, Venditti A, Del Poeta G, et al, &ldquo;High-Dose Chemotherapy in Adult Acute Myeloid Leukemia: Rationale and Results,&rdquo; <i>Leuk Res</i>, 1996, 20(7):535-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/8795687/pubmed\" target=\"_blank\" id=\"8795687\">8795687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone RM, Berg DT, George SL, et al, &ldquo;Postremission Therapy in Older Patients With <i>de novo</i> Acute Myeloid Leukemia: A Randomized Trial Comparing Mitoxantrone and Intermediate-Dose Cytarabine With Standard-Dose Cytarabine,&quot; <i>Blood</i>, 2001, 98(3):548-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/11468148/pubmed\" target=\"_blank\" id=\"11468148\">11468148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Storring JM, Minden MD, Kao S, et al, &ldquo;Treatment of Adults With BCR-ABL Negative Acute Lymphoblastic Leukaemia With a Modified Paediatric Regimen,&rdquo; <i>Br J Haematol</i>, 2009, 146(1):76-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/19438471/pubmed\" target=\"_blank\" id=\"19438471\">19438471</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tilly H, Castaigne S, Bordessoule D, et al, &ldquo;Low-Dose Cytarabine Versus Intensive Chemotherapy in the Treatment of Acute Nonlymphocytic Leukemia in the Elderly,&rdquo; <i>J Clin Oncol</i>, 1990, 8(2):272-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/2299370/pubmed\" target=\"_blank\" id=\"2299370\">2299370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA, King KM, Zhang Y, et al, &ldquo;Physical and Chemical Stability of Methotrexate, Cytarabine, and Hydrocortisone in Elliott's B Solution for Intrathecal Use,&rdquo; <i>J Oncol Pharm Pract</i>, 2002, 8(1):27-32.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Truica CI and Frankel SR, &ldquo;Acute Rhabdomyolysis as a Complication of Cytarabine Chemotherapy for Acute Myeloid Leukemia: Case Report and Review of Literature,&rdquo; <i>Am J Hematol</i>, 2002, 70(4):320-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/12210815/pubmed\" target=\"_blank\" id=\"12210815\">12210815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18182662\"></a>Tsimberidou AM, Wierda WG, Plunkett W, et al, &quot;Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia,&quot; <i>J Clin Oncol</i>, 2008, 26(2):196-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/18182662/pubmed\" target=\"_blank\" id=\"18182662\">18182662</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15800666\"></a>van Imhoff GW, van der Holt B, MacKenzie MA, et al, &ldquo;Short Intensive Sequential Therapy Followed by Autologous Stem Cell Transplantation in Adult Burkitt, Burkitt-Like and Lymphoblastic Lymphoma,&rdquo; <i>Leukemia</i>, 2005, 19(6):945-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/15800666/pubmed\" target=\"_blank\" id=\"15800666\">15800666</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3334893\"></a>Velasquez WS, Cabanillas F, Salvador P, et al, &ldquo;Effective Salvage Therapy for Lymphoma With Cisplatin in Combination With High-Dose Ara-C and Dexamethasone (DHAP),&rdquo; <i>Blood</i>, 1988, 71(1):117-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/3334893 /pubmed\" target=\"_blank\" id=\"3334893 \">3334893 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8201379\"></a>Velasquez WF, McLaughlin P, Tucker S, et al, &ldquo;ESHAP - An Effective Chemotherapy Regimen in Refractory and Relapsing Lymphoma: A 4-Year Follow-up Study,&rdquo; <i>J Clin Oncol</i>, 1994, 12(6):1169-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/8201379 /pubmed\" target=\"_blank\" id=\"8201379 \">8201379 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. <i>J Clin Oncol</i>. 1992, 10(7):1103-1111.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/1607916 /pubmed\" target=\"_blank\" id=\"1607916 \">1607916 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss MA, Aliff TB, Tallman MS, et al, &ldquo;A Single, High Dose of Idarubicin Combined With Cytarabine as Induction Therapy for Adult Patients With Recurrent or Refractory Acute Lymphoblastic Leukemia,&rdquo; <i>Cancer</i>, 2002, 95(3):581-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/12209751/pubmed\" target=\"_blank\" id=\"12209751\">12209751</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wenzell CM, Gallagher EM, Earl M, et al. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. <i>Am J Hematol</i>. 2013;88(10):906-909. doi: 10.1002/ajh.23530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/23828018/pubmed\" target=\"_blank\" id=\"23828018\">23828018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18076637\"></a>Wierzbowska A, Robak T, Pluta A, et al, &ldquo;Cladribine Combined With High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) is a Highly Effective Salvage Regimen in Patients With Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group,&rdquo; <i>Eur J Haematol</i> 2008; 80(2):115-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/18076637/pubmed\" target=\"_blank\" id=\"18076637\">18076637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1730080\"></a>Wiernik PH, Banks P, Case Jr DC, et al, &ldquo;Cytarabine Plus Idarubicin or Daunorubicin as Induction and Consolidation Therapy for Previously Untreated Adult Patients With Acute Myeloid Leukemia,&rdquo; <i>Blood</i>, 1992, 79(2):313-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/1730080/pubmed\" target=\"_blank\" id=\"1730080\">1730080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. <i>J Clin Oncol</i>. 2014;32(3):219-228. doi: 10.1200/JCO.2013.51.8571.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/24297940/pubmed\" target=\"_blank\" id=\"24297940\">24297940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wittbrodt ET and Aviles VM, &ldquo;Pancreatitis and Fatal ARDS Following High-Dose Cytarabine Induction for Acute Myelogenous Leukemia,&rdquo; <i>J Oncol Pharm Pract</i>, 1997, 3(2):110-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Woods WG, Ruymann FB, Lampkin BC, et al, &ldquo;The Role of Timing of High-Dose Cytosine Arabinoside Intensification and of Maintenance Therapy in the Treatment of Children With Acute Nonlymphocytic Leukemia,&rdquo; <i>Cancer</i>, 1990, 66(6):1106-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/2205352/pubmed\" target=\"_blank\" id=\"2205352\">2205352</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12930315\"></a>Wrzesie&#324;-Ku&#347; A, Robak T, Lech-Mara&#324;da E, et al, &ldquo;A Multicenter, Open, Non-Comparative Phase II Study of the Combination of Cladribine (2-Chlorodeoxyadenosine), Cytarabine, and G-CSF as Induction Therapy in Refractory Acute Myeloid Leukemia &ndash; A Report of the Polish Adult Leukemia Group (PALG),&rdquo; <i>Eur J Haematol</i>, 2003;71(3):155&ndash;62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-drug-information/abstract-text/12930315/pubmed\" target=\"_blank\" id=\"12930315\">12930315</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9314 Version 184.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708668\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F155998\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F156050\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F156002\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F156029\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F156003\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F156004\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F156005\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20340178\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F155976\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F155961\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F155979\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130965\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F155977\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722038\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F156059\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F155968\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F155982\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F155965\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299114\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F155970\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F155972\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F155985\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5375699\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F155974\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F155964\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F155981\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323088\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F155986\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9314|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cytarabine-patient-drug-information\" class=\"drug drug_patient\">Cytarabine: Patient drug information</a></li><li><a href=\"topic.htm?path=cytarabine-pediatric-drug-information\" class=\"drug drug_pediatric\">Cytarabine: Pediatric drug information</a></li></ul></div></div>","javascript":null}